HC
CRSP icon

Hurley Capital’s CRISPR Therapeutics CRSP Stock Holding History

Hurley Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-25
Closed -$8.13K – 629
2025
Q3 		$8.13K Buy
+25
New +$1.44K ﹤0.01% 385

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Hurley Capital's CRSP Position: Q1 2026 in Review

Hurley Capital opened a new position in CRISPR Therapeutics (CRSP) in Q1 2026: 80 shares worth $3.81K. The stake represents ﹤0.01% of the portfolio and ranks #494 among its holdings. This is a return to the name: Hurley Capital previously reported a position in CRSP as recently as Q3 2025.

Hurley Capital first reported a position in CRSP in Q3 2025 and has held it in 2 quarters since. The position peaked at $5.18K in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Hurley Capital held 80 shares of CRISPR Therapeutics worth $3.81K as of Q1 2026.
  • CRISPR Therapeutics was a new Hurley Capital position in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Hurley Capital's portfolio in Q1 2026, its #494 holding.
  • Hurley Capital first reported a position in CRISPR Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Hurley Capital's CRISPR Therapeutics position peaked at $5.18K in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Hurley Capital's 13F filing for Q1 2026, filed 6 May 2026.